Truist Financial Forecasts Strong Price Appreciation for Fresenius Medical Care (NYSE:FMS) Stock

Fresenius Medical Care (NYSE:FMS - Free Report) had its price objective raised by Truist Financial from $25.00 to $30.00 in a research report sent to investors on Monday morning,Benzinga reports. They currently have a hold rating on the stock.

Separately, StockNews.com raised shares of Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th.

Fresenius Medical Care Stock Performance

Shares of NYSE:FMS traded up $0.36 during midday trading on Monday, hitting $28.76. The stock had a trading volume of 384,957 shares, compared to its average volume of 324,378. The company has a market capitalization of $16.87 billion, a PE ratio of 23.77, a P/E/G ratio of 0.76 and a beta of 0.85. The stock has a 50 day moving average price of $24.98 and a two-hundred day moving average price of $23.67. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. Fresenius Medical Care has a 1 year low of $17.93 and a 1 year high of $28.80.

Fresenius Medical Care (NYSE:FMS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.01. The business had revenue of $5.54 billion for the quarter, compared to the consensus estimate of $4.71 billion. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. As a group, equities analysts predict that Fresenius Medical Care will post 1.51 earnings per share for the current fiscal year.

Fresenius Medical Care Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 23rd will be issued a dividend of $0.7871 per share. The ex-dividend date of this dividend is Friday, May 23rd. This represents a yield of 1.9%. This is an increase from Fresenius Medical Care's previous annual dividend of $0.44. Fresenius Medical Care's payout ratio is currently 49.11%.

Institutional Trading of Fresenius Medical Care

A number of institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC boosted its holdings in Fresenius Medical Care by 50.0% during the first quarter. Millennium Management LLC now owns 1,083,602 shares of the company's stock worth $26,982,000 after buying an additional 361,364 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Fresenius Medical Care by 14.2% in the first quarter. AQR Capital Management LLC now owns 14,297 shares of the company's stock valued at $356,000 after purchasing an additional 1,777 shares in the last quarter. Advisors Asset Management Inc. lifted its holdings in shares of Fresenius Medical Care by 243.3% in the first quarter. Advisors Asset Management Inc. now owns 7,817 shares of the company's stock valued at $195,000 after purchasing an additional 5,540 shares in the last quarter. Vident Advisory LLC lifted its holdings in shares of Fresenius Medical Care by 131.8% in the first quarter. Vident Advisory LLC now owns 54,274 shares of the company's stock valued at $1,351,000 after purchasing an additional 30,864 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Fresenius Medical Care by 5.0% in the first quarter. Northern Trust Corp now owns 380,251 shares of the company's stock valued at $9,468,000 after purchasing an additional 18,061 shares in the last quarter. Hedge funds and other institutional investors own 8.37% of the company's stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.